Trial Outcomes & Findings for I-scan for Adenoma Detection (NCT NCT02811419)
NCT ID: NCT02811419
Last Updated: 2019-05-01
Results Overview
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
740 participants
Primary outcome timeframe
12 months
Results posted on
2019-05-01
Participant Flow
Participant milestones
| Measure |
Intervention (I-scan)
i-scan 1 (surface enhancement with contrast enhancement)
|
Control (HDWL)
HDWL (High definition white light)
|
|---|---|---|
|
Overall Study
STARTED
|
369
|
371
|
|
Overall Study
COMPLETED
|
357
|
358
|
|
Overall Study
NOT COMPLETED
|
12
|
13
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
I-scan for Adenoma Detection
Baseline characteristics by cohort
| Measure |
I-scan
n=369 Participants
Inspection with i-scan surface enhancement
i-scan: examination will be performed with i-scan digital enhancement
|
Standard High-definition White Light
n=371 Participants
Inspection with standard high-definition white light (usual care)
standard high-definition white light: examination will be performed with high-definition white light
|
Total
n=740 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
61.4 years
STANDARD_DEVIATION 7.5 • n=5 Participants
|
60.8 years
STANDARD_DEVIATION 7.5 • n=7 Participants
|
61.1 years
STANDARD_DEVIATION 7.5 • n=5 Participants
|
|
Sex: Female, Male
Female
|
185 Participants
n=5 Participants
|
187 Participants
n=7 Participants
|
372 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
184 Participants
n=5 Participants
|
184 Participants
n=7 Participants
|
368 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
369 Participants
n=5 Participants
|
371 Participants
n=7 Participants
|
740 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
369 participants
n=5 Participants
|
371 participants
n=7 Participants
|
740 participants
n=5 Participants
|
|
body mass index
|
27.0 kg/m^2
STANDARD_DEVIATION 5.7 • n=5 Participants
|
26.5 kg/m^2
STANDARD_DEVIATION 4.9 • n=7 Participants
|
26.7 kg/m^2
STANDARD_DEVIATION 5.2 • n=5 Participants
|
PRIMARY outcome
Timeframe: 12 monthsOutcome measures
| Measure |
Intervention (I-scan)
n=369 Participants
i-scan 1 (surface enhancement with contrast enhancement)
|
Control (HDWL)
n=371 Participants
HDWL (High definition white light)
|
|---|---|---|
|
Number of Participants With Conventional Adenoma and Sessile Serrated Adenoma/Polyp Detected
|
208 Participants
|
171 Participants
|
SECONDARY outcome
Timeframe: 12 monthsOutcome measures
| Measure |
Intervention (I-scan)
n=369 Participants
i-scan 1 (surface enhancement with contrast enhancement)
|
Control (HDWL)
n=371 Participants
HDWL (High definition white light)
|
|---|---|---|
|
Number of Participants With Conventional Adenoma Detected
|
174 Participants
|
140 Participants
|
Adverse Events
Intervention (I-scan)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Control (HDWL)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Trilokesh Kidambi
University of California San Francisco
Phone: 909-973-0629
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place